QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

CTNM

QT50Contineum Therapeutics, Inc. Class A Common Stock
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
11.94
-0.22-1.81%
OverviewShort InterestFilings
CTNMQT50Contineum Therapeutics, Inc. Class A Common Stock·NASDAQ
OverviewShort InterestFilings
11.94-1.81%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-
Insider Own4.01%
Shs Outstand37.39M
Perf Week0.67%
Market Cap454.62MForward P/E-EPS next Y-1.81Insider Trans-0.01%Shs Float-Perf Month-6.43%
Enterprise Value441.41MPEG1.86EPS next Q-0.46Inst Own-Short Float-Perf Quarter-1.40%
Income-58509376.00P/S0.00EPS this Y-Inst Trans-Short Ratio-Perf Half Y3.38%
Sales-P/B1.82EPS next Y-10.15%ROA-22.36%Short Interest-Perf YTD4.46%
Book/sh6.69P/C-EPS next 5Y-ROE-27.09%52W High16.33 -26.88%Perf Year203.82%
Cash/sh6.58P/FCF-EPS past 3/5Y-ROIC-26.01%52W Low3.57 234.45%Perf 3Y-
Dividend Est.-EV/EBITDA-7.60Sales past 3/5Y-Gross Margin0.00%Volatility6.18% 4.67%Perf 5Y-
Dividend TTM-EV/Sales0.00EPS Y/Y TTM-19.63%Oper. Margin0.00%ATR (14)0.91Perf 10Y-
Dividend Ex-Date-Quick Ratio38.00Sales Y/Y TTM-Profit Margin0.00%RSI (14)42.86Recom2.33
Dividend Gr. 3/5Y-Current Ratio38.00EPS Q/Q37.10%SMA20-4.92%Beta0.62Target Price16.00
Payout0.00%Debt/Eq0.03Sales Q/Q-SMA50-8.39%Rel Volume1.34Prev Close12.16
Employees41LT Debt/Eq0.02EarningsAug 04SMA200-4.49%Avg Volume233.51KPrice11.94
IPO DateApr 05, 2024Option/ShortYes / YesEPS/Sales Surpr.29.09% -Net Debt/EBITDA0.23Volume313,870Change-1.81%
Analyst Ratings
DateActionAnalystRatingTarget
May-14-26ReiteratedMorgan StanleyEqual Weight$14 → $16
Jan-08-26DowngradeMorgan StanleyOverweight → Equal Weight$14
Nov-24-25ReiteratedRobert W. Baird$16 → $14
Nov-21-25ReiteratedRBC CapitalOutperform$30 → $22
Sep-25-25InitiatedLeerinkOutperform$20
Mar-07-25ReiteratedRobert W. Baird$32 → $16
Oct-21-24ReiteratedRobert W. Baird$32
Apr-30-24InitiatedRBC CapitalOutperform$30
Apr-30-24ReiteratedStifel Nicolaus$29
Latest News
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
Total Revenue0050
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A
000
Gross Profit0050
Selling, General and Administrative Excl. Other17126
Research and Development523828
Other Operating Expense-1132
Operating Income-68-51-16
Interest Expense
000
Unusual Expense
———
Non-Operating Income (Expense)-8-9-39
Net Income Before Taxes-60-4223
Income Taxes
000
Consolidated Net Income-60-4223
Net Income From Continuing Operations-60-4223
Net Income-60-4223
EPS (Recurring)-2.17-1.630.13
EPS (Basic, Before Extraordinaries)-2.17-1.630.13
EPS (Diluted)-2.17-1.630.13
EBITDA-60-4224
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio
———
Gross Margin——100.00
Operating Margin——-32.00
Net Margin——46.00
Shares Outstanding282625
Market Capitalization320——
Operating Lease Expense
———
Insider Trading Volume
$12.81$11.62$10.44$9.26$8.07● Close Price0.00K80.15K160.30K240.45K320.60KUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Lorrain Daniel S.Chief Scientific OfficerJun 01 '26Sale13.164,17054,862139,372Jun 01 12:00 AM
Lorrain Daniel S.Chief Scientific OfficerMay 01 '26Sale13.124,17054,694143,542May 01 12:00 AM
Lorrain Daniel S.Chief Scientific OfficerApr 06 '26Sale13.434,17056,014147,712Apr 06 12:00 AM
Watkins TimCMO & Head of DevelopmentMar 02 '26Sale15.023,61154,2200Mar 02 12:00 AM
Lorrain Daniel S.Chief Scientific OfficerMar 02 '26Sale15.014,17062,585151,882Mar 02 12:00 AM
Watkins TimCMO & Head of DevelopmentMar 02 '26Option Exercise4.507,22232,500249,167Mar 02 12:00 AM
Lorrain Daniel S.Chief Scientific OfficerFeb 25 '26Option Exercise1.017,6487,724159,876Feb 26 12:00 AM
Stengone Carmine N.CEO and PresidentFeb 25 '26Option Exercise1.265,4006,804120,917Feb 26 12:00 AM
Stengone Carmine N.CEO and PresidentFeb 25 '26Sale16.022,70043,24214,954Feb 26 12:00 AM
Lorrain Daniel S.Chief Scientific OfficerFeb 25 '26Sale16.013,82461,228156,052Feb 26 12:00 AM
Stengone Carmine N.CEO and PresidentFeb 24 '26Option Exercise1.268,80011,088123,617Feb 26 12:00 AM
Stengone Carmine N.CEO and PresidentFeb 24 '26Sale16.024,40070,48614,954Feb 26 12:00 AM
Lorrain Daniel S.Chief Scientific OfficerFeb 24 '26Option Exercise1.018,6008,686160,352Feb 26 12:00 AM
Lorrain Daniel S.Chief Scientific OfficerFeb 24 '26Sale16.034,30068,936156,052Feb 26 12:00 AM
Lorrain Daniel S.Chief Scientific OfficerFeb 19 '26Option Exercise1.01200202156,152Feb 20 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR